I haven't had a chance to think through this more carefully, but has this CMO move minimised any litigation risks associated with the Exelogen lawsuit (vs University of Birmingham)?
Tom mentions the following in his response: "In my view, an orphan designation offers superior, legislative protection than a patent ever will (which can be potentially litigated and objected as to its validity". I understand that he is not referring to the Exelogen situation, but rather, patent infringements etc.
Thoughts?
Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-67
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 84879 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 3500 | 1 |
View Market Depth
| Last trade - 07.00am 06/11/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable